For researchers, journalists and editors
Cite, quote and reuse our data
Everything we publish as original data is free to cite, quote and embed under CC BY 4.0, provided the source is named and linked. This page lists what is citable, gives you the citation strings, and tells you who is available to comment on the record.
- Licence:
- CC BY 4.0 with attribution
- Last updated:
- Media contact:
- via the contact page
How do I cite StemCell Longevita data?
Cite the specific report page rather than the homepage, name StemCell Longevita as the publisher, and include the retrieval date because our reports are revised on a stated cycle. Tables and charts may be reproduced or embedded unchanged with a visible link back to the source page. If you need a figure we have not published, ask — we would rather give you the underlying method than see an estimate attributed to us.
- Licence
- CC BY 4.0, attribution required
- Citable assets
- 8 published reports, tables and policies
- Embeddable
- 3 script-free charts and tables
- Expert comment
- On the record, attributed to a named physician
What is citable
These are the pages that contain original data, method or policy. Everything else on the site is educational content built on third-party literature and should be cited to the underlying source instead.
| Asset | Type | Edition | Reuse |
|---|---|---|---|
| International Stem Cell Therapy Cost Comparison 2027 Package ranges for Türkiye are our own written-quote data; comparator markets are sourced and footnoted on the page. | Report with price tables | 2027 edition | PDF · Embed · Cite |
| International Patient Cost Transparency Report 2026 What we quote, what moves a quote, and what is excluded. | Report | 2026 edition | Cite |
| Laboratory Transparency Report: MSC release testing The actual release panel, acceptance criteria and traceability chain. | Report with method tables | Rolling | Embed · Cite |
| International Patient Outcomes Registry Protocol Protocol only. Outcome figures publish after the first audited data cut; no interim numbers are circulated. | Protocol and data dictionary | v1 | Cite |
| International Regenerative Medicine Patient Trends 2027 Methodology and reporting frame published ahead of fieldwork. | Survey methodology | 2027 frame | Cite |
| Evidence at a glance: condition-by-condition maturity Human studies, randomised trials, outcome durability and regulatory status per indication. | Structured evidence appraisal | Rolling | Embed · Cite |
| How we evaluate evidence (editorial and evidence policy) Grading rules, review cadence, correction policy and disclosure. | Policy | Rolling | Cite |
| MSC regulatory status by country Jurisdiction-by-jurisdiction regulatory framing with named regulators. | Reference table | Rolling | Cite |
Ready-made citations
| Style | Citation |
|---|---|
| APA 7 | StemCell Longevita. (2026). International stem cell therapy cost comparison 2027. Retrieved from https://stemcelllongevita.com/stem-cell-therapy-cost-turkey |
| Vancouver | StemCell Longevita. International stem cell therapy cost comparison 2027 [Internet]. Istanbul: StemCell Longevita; 2026 [cited 2026-08-23]. Available from: https://stemcelllongevita.com/stem-cell-therapy-cost-turkey |
| MLA 9 | StemCell Longevita. "International Stem Cell Therapy Cost Comparison 2027." StemCell Longevita, 2026, https://stemcelllongevita.com/stem-cell-therapy-cost-turkey. |
BibTeX:
@techreport{longevita_cost_2027,
title = {International Stem Cell Therapy Cost Comparison 2027},
author = {{StemCell Longevita}},
institution = {StemCell Longevita},
year = {2026},
url = {https://stemcelllongevita.com/stem-cell-therapy-cost-turkey},
urldate = {2026-08-23}
}Embeddable charts and tables
Each embed is a single static HTML file with a visible source line and a canonical link back to the report it came from. Copy the snippet as-is.
Cost comparison 2027
Self-contained, no tracking and no third-party scripts. It renders the same figures as the source page and carries the attribution line inside the frame.
<iframe src="https://stemcelllongevita.com/embed/cost-comparison.html" width="100%" height="520" loading="lazy" title="Cost comparison 2027 — StemCell Longevita" style="border:1px solid #dde5e8;border-radius:12px"></iframe>
<p><a href="https://stemcelllongevita.com/cite">Source: StemCell Longevita</a></p>Evidence maturity by indication
Self-contained, no tracking and no third-party scripts. It renders the same figures as the source page and carries the attribution line inside the frame.
<iframe src="https://stemcelllongevita.com/embed/evidence-maturity.html" width="100%" height="560" loading="lazy" title="Evidence maturity by indication — StemCell Longevita" style="border:1px solid #dde5e8;border-radius:12px"></iframe>
<p><a href="https://stemcelllongevita.com/cite">Source: StemCell Longevita</a></p>MSC batch release panel
Self-contained, no tracking and no third-party scripts. It renders the same figures as the source page and carries the attribution line inside the frame.
<iframe src="https://stemcelllongevita.com/embed/lab-release-panel.html" width="100%" height="520" loading="lazy" title="MSC batch release panel — StemCell Longevita" style="border:1px solid #dde5e8;border-radius:12px"></iframe>
<p><a href="https://stemcelllongevita.com/cite">Source: StemCell Longevita</a></p>Downloadable reports
- International Stem Cell Therapy Cost Comparison 2027 (PDF) — 2027 edition
- All reports are readable in full on the web with no registration.
- Condition guides are downloadable PDFs for patients.
Expert comment and speaker requests
We publish expert contributions under named physicians with their credentials, affiliations and review dates, never under a house byline. Conference programmes, society listings and editors can use the biography and topics below.
Prof. Dr. Erdal Karaöz
Medical Director, cell biology and stem cell research
Available for comment on:
- mesenchymal stromal cell manufacturing and release testing
- Wharton's jelly derived MSC biology
- evidence appraisal in regenerative medicine
- patient selection and candidacy in cross-border care
Full credentials, affiliations and publication history are on each physician profile.
Where we seek references
Our reference strategy is editorial, not transactional. We contribute where a named clinician can stand behind what is said, and we publish the register below so anyone can check how a reference to us came about.
| Channel | What we contribute |
|---|---|
| Medical and scientific societies | Society membership pages, working-group listings and society meeting abstracts under named physicians. |
| University and institutional pages | Faculty, affiliated-laboratory and research-group listings that name our clinicians and their institutions. |
| Conference programmes | Speaker biographies, session listings and downloadable programme PDFs from regenerative-medicine meetings. |
| PubMed and ORCID author profiles | Indexed publications linked from each physician profile page, so the person entity resolves consistently. |
| Hospital and institutional pages | Partner hospital consultant listings and departmental pages for hospital-based care. |
| Professional and medical directories | Verified clinician and clinic directory entries with consistent name, address and credentials. |
| Academic and press interviews | On-record interviews and expert comment given by named physicians, not by the brand. |
| Reputable health publications | Fact-checkable expert contributions and corrections offered to health desks. |
| Scientific podcasts | Long-form technical discussion where claims can be qualified properly. |
Reuse rules
- Attribute to StemCell Longevita and link to the specific source page.
- Do not alter figures, table rows or axis ranges. Crop for layout only.
- Keep the qualifying note attached to any evidence or outcome figure; the caveat is part of the data.
- State the retrieval date. Reports are revised on the cycle printed on each report page.
- We do not pay for placements, and we do not offer content in exchange for links.
- If we get something wrong, tell us and we will publish a dated correction under our editorial policy.